Sat, Nov 29, 2014, 5:29 AM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

OncoGenex Pharmaceuticals, Inc. Message Board

  • tnk.shorting tnk.shorting Oct 25, 2013 10:55 AM Flag

    Quick mention by AF

    Nothing of import, but on the radar screen. From his Biotech Mailbag column released today (note: OGXI isn't the only company referenced):

    "To select the next test cases for the Feuerstein-Ratain Rule, I ran a screen using BioMedTracker for companies with cancer drugs in phase III studies expected to announce top-line results within the next six months.

    "Remember, the F-R Rule tries to predict the outcome of phase III studies of cancer drugs based on the market cap of the company conducting the study four months prior to the expected results.

    "Here's what I came up with:

    "Oncogenex Pharmaceuticals (OGXI_): The "Synergy" study of custirsen in combination with docetaxel in first-line prostate cancer patients should have survival results ready in mid-2014. That timeline makes Oncogenex a bit early for assessment by the F-R Rule but keep it in mind."

    Sentiment: Hold

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
OGXI
2.110.0000(0.00%)Nov 28 1:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.